Credit: Canva
Low-dose CT chest scans could help detect pneumonia in at-risk patients while exposing them to only small amounts of radiation, a new study has found. The research, published in Radiology: Cardiothoracic Imaging, shows that ultra-low-dose scans can effectively detect pneumonia in patients with compromised immune systems, enabling doctors to treat the infection before it becomes life-threatening. According to the researchers, these scans expose patients to just 2% of the radiation dose used in a standard CT scan.
"This study paves the way for safer, AI-driven imaging that reduces radiation exposure while preserving diagnostic accuracy,” lead researcher Dr Maximiliano Klug, a radiologist with the Sheba Medical Center in Ramat Gan, Israel, said in a news release. He added that CT scans are the gold standard for detecting pneumonia but there are concerns regarding the risk posed by repeated exposure to radiation. There is a solution- ultra-low-dose CT scan. However, the problem is that these scans can be grainy and hard to read, researchers said.
Study Gives Solution To This
To overcome that, Klug's team developed an AI program that could help "de-noise" low-dose scans, making them sharper and easier to read. Between September 2020 and December 2022, 54 patients with compromised immune systems who had fevers underwent a pair of chest CT scans -- a normal dose scan and an ultra-low-dose scan. The AI program cleaned up the low-dose scan, and then both sets of images were given to a pair of radiologists for assessment. Radiologists had 100% accuracy in detecting pneumonia and other lung problems with the AI-cleaned low-dose scans, but 91% to 98% accuracy in examining the scans that hadn’t been improved through AI, results show.
"This pilot study identified infection with a fraction of the radiation dose," Klug said. "This approach could drive larger studies and ultimately reshape clinical guidelines, making denoised ultra-low dose CT the new standard for young immunocompromised patients.
How Can You Detect Pneumonia?
Pneumonia is a lung infection that causes the air sacs in the lungs to fill with fluid or pus and can be caused by bacteria, viruses, or fungi. The symptoms can range from milk to severe, which includes:
Coughing with or without cough
Fever
Chills
Trouble breathing
Chest pain, especially when breathing deeply or coughing
Sweating or chills
Rapid heart rate
Loss of appetite
Bluish skin, lips, and nails
Confusion.
How to detect Pneumonia in coughing newborns and toddlers?
Pneumonia can severely affect newborns and young children as their lungs are comparatively more sensitive. As per Dr Goyal, young children can cough for various reasons including seasonal infections and tonsillitis, which is very common in this age group. But if they look visibly irritable and have poor sleep patterns, then parents must reach out to an expert. "I am not saying that parents must visit a hospital but any local paediatrician would be able to detect pneumonia in your kid.
Credit: AI
Retatrutide, an experimental loss drug being called the 'Godzilla' of weight loss jabs, has been reported to cause 129 symptoms, including burning sensation on skin, panic attack, a racing heartbeat and depression. It earned the nickname after clinical trials indicated that it could be more powerful than Ozempic and Mounjaro.
The discovery has raised concerns, especially amid the growing use of the drug outside clinical trials. Retatrutide is still being studied and has not yet been approved for general use but it is being bought illegally in the UK as well as across the world.
According to Daily Mail, researchers from the University of Pennsylvania, analysed 148,640 Reddit posts related to retatrutide and identified 13,589 users who claimed to be taking retatrutide and analysed the side effects they reported. Of these, 7,823 reported at least one side effect, researchers identified 129 different symptoms.
The reports included physical symptoms as well as psychological complaints. But it does not prove that this weight loss drug is directly responsible for these side effects. The study was published in JAMA Network Open.
Social media reports can help identify safety concerns, but they have limitations. Researchers cannot independently verify every user’s medical history, the product they took, its ingredients or whether another condition could explain their symptoms.
The side effects were split into 14 different categories, including gastrointestinal problems, mental disorders, heart problems and skin changes. The most common side effect was increased appetite surprisingly which was seen in almost one in five users, affecting 1,336 people.
Fatigue was the second most reported symptom, which was flagged by around 15% of the users, which means almost 1, 188 patients. Nausea, on the other hand, was on top of the list of gastrointestinal issues, affecting fewer than one in 10.
Retatrutide is being developed by pharmaceutical company Eli Lilly as a treatment for obesity. It works on three hormone receptors involved in regulating appetite, blood sugar and energy balance: GIP, GLP-1 and glucagon.
The drug has attracted attention because clinical trials have shown substantial weight loss. In a Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose lost an average of 24.2% of their body weight over 48 weeks.
It also delivered nearly 21% average weight loss in people with type 2 diabetes and obesity, according to results from a large Phase 3 trial published in The Lancet.
In the TRIUMPH-2 trial, people who received the highest 12 mg dose lost an average of 20.8% of their body weight over 80 weeks, equivalent to about 49.6 pounds or 22.5 kg.
However, promising results do not mean the drug is suitable for unsupervised use, especially since it is unapproved.
Also read: 2 Indians Charged In US Over Fake Ozempic Scheme: How To Spot Counterfeit GLP-1 Drugs
In controlled clinical trials, the most frequently reported side effects have included nausea, diarrhoea, vomiting and constipation. These gastrointestinal problems were generally more common at higher doses and during dose increases.
Researchers have also reported increased heart rate and skin sensitivity in some participants. In the Phase 2 trial, adverse events related to skin sensitivity were reported in 7% of participants receiving retatrutide, compared with 1% in the placebo group.
The symptoms reported in online discussions, including panic attacks and depression, require careful interpretation. Their appearance in user posts does not, by itself, prove that the drug caused them or establish how frequently they occur among people taking retatrutide under medical supervision.
Retatrutide remains under study, which means its safety profile is still being assessed by researchers. Products sold online or through unlawful ways may not contain the right advertised drug.
Professor Naveed Sattar, professor of cardiometabolic medicine at the University of Glasgow, warned against purchasing unlicensed weight-loss products online. “I would urge people to avoid buying unlicensed weight-loss products online,” he said, according to Daily Mail. “There is no certainty about what these products contain, and without proper regulatory oversight there is a risk of adverse effects.”
Credit: Reuters
Indonesia’s Central Kalimantan and Sumatra are shrouded in thick orange-yellow smog as wildfires rage across the regions. The smoke has spread across Southeast Asia, obscuring Singapore’s skyline, reaching the Philippines and forcing school closures in parts of Malaysia.
Indonesia’s Air Pollution Standard Index (ISPU) exceeded 1,200 on Wednesday, more than four times the “hazardous” threshold of 300, according to Environment Ministry data.
Fueled by El Niño-related dry conditions, the country is experiencing its most intense wildfire season in 11 years since mid-July. Authorities have recorded more than 280,000 respiratory problems in haze-affected regions since August 18, as fires burned through hundreds of thousands of hectares across Borneo and Sumatra.
Indonesia plans to deploy 1.5 tons of dry ice, the solid form of carbon dioxide, over South Sumatra using Cessna aircraft to reduce the haze. The trial will focus on the Palembang area, with the approach potentially extended to other regions if successful, BBC reported.
Dry ice can cool the air and encourage cloud formation under suitable atmospheric conditions. However, its effectiveness in reducing wildfire haze will depend on local weather conditions and the method used.

The smoke has reached Singapore, Malaysia, East Timor and the Philippines. Singapore’s National Environment Agency reported its highest air pollution warning level in the western part of the country on Wednesday. Fine particulate pollution also exceeded the World Health Organization’s recommended annual average exposure level, BBC reported.
Singapore has introduced subsidies for haze-related medical treatment and begun distributing N95 masks to eligible residents during periods of very unhealthy air pollution.
Read More: Delhi Air Pollution Is Back: What Days Of Poor AQI Can Do to Your Lungs
A 2025 study published in Epidemiology found that the effects of wildfire smoke exposure on the heart and lungs may persist for up to three months after the smoke clears. Higher smoke pollution levels were also associated with an increased risk of health problems.
Wildfire smoke contains fine particulate matter called PM2.5, which can penetrate deep into the lungs. Some particles can enter the bloodstream and trigger inflammation.
Smoke may also contain toxic substances released by burning plastics, homes, vehicles, electronics and industrial materials.
Prolonged exposure can affect several aspects of health:
Children, older adults and people with existing heart or lung conditions are particularly vulnerable.
Even after visible smoke clears, harmful particles may remain in the air. To reduce exposure:
Credit: AI
India's Union Health Ministry has been asked to examine concerns over the safety and quality of coronary stents.
This comes after three models of drug-eluting stents (DES) made by India-based medical device company, Meril Life Sciences Pvt. Ltd, were reportedly withdrawn in Sri Lanka over quality issues.
Sri Lanka drug regulatory body, National Medicines Regulatory Authority (NMRA), reportedly issued the instructions for withdrawal of these stents in June 2026. The Cabinet Secretariat urged the Health Ministry to look into the concerns on October 5, after a representation by Rajya Sabha member Ajeet Madhav Gopchade who is also a medical doctor.
According to Sri Lanka Mirror, the concerns include improper stent positioning, stent dislodgement, acute stent thrombosis, and failure of the devices to expand adequately after implantation.
Stent thrombosis occurs when a blood clot forms inside the implanted stent, potentially blocking blood flow to the heart. Acute stent thrombosis is particularly serious because it can lead to a heart attack and requires urgent medical attention.
These complications can affect the success of a procedure and may put patients' lives at risk.
These issues were identified after an investigation was conducted by the Medical Device Evaluation Committee (MDEC) of the NMRA. The regulatory body also said that these defects necessitate the use of supplementary devices, which resulted in wastage of precious time and unnecessary added expenses.
In his representation, Gopchade addresses the media reports about the withdrawal of three stent models in Sri Lanka.
Also read: Mammogram May Spot Hidden Heart Risk That Doctors Miss In Women
Gopchade urged the government to assess whether India's regulatory system needs further strengthening to address risks that come after coronary stent implantation.
In his letter dated October 5, he said the reported developments required closer scrutiny to protect patients. “These reports highlight that Indian-patient-safety issues that India needs to examine carefully and address proactively,” he said in the representation, according to The Economic Times.
He called for rigorous device testing, clinical decision-making, and monitoring of complications after stent implantation. He said that safety checks should not end once a medical device has received regulatory approval.
Gopchade called for better documentation to ensure that stents are used only when medically indicated, and that alternative treatments are considered first.
He also proposed stronger monitoring of the performance of medical devices after they enter routine clinical use. Such monitoring can help spot complications that may not have been apparent during initial testing.
Gopchade further urged the government to establish a mechanism for reviewing safety alerts, recalls and withdrawals issued by foreign regulators effectively.
This would help authorities assess whether a device flagged overseas is also being marketed or used in India and whether investigation is needed.
Coronary stents are small, mesh-like tubes that are placed inside narrowed or blocked coronary arteries to help restore blood flow to the heart. They are used during angioplasty, a procedure that opens blocked arteries in people with coronary artery disease.
Drug-eluting stents release medication over time to reduce the risk of the artery narrowing again. While these devices can help restore blood flow and improve cardiovascular health, their safety depends on their quality, correct placement, and post-procedure care.
© $2026 Times Horizon Private Limited